No abstract

In order to solve the problems of high power consumption and low output damping force of magnetorheological dampers, the relationship model between the structural parameters and the optimization objectives of dampers is established with the low power consumption and lightweight of magnetorheological dampers. The key structural parameters of the magnetorheological damper are optimized by the multi‐objective genetic algorithm, and the optimal solution is obtained, and the optimized magnetorheological damper is tested and studied. The rationality of the selected parameters is verified by experimental study. The results show that the power consumption of magnetorheological dampers is reduced by 43 % and the damping force is increased by 30 % after optimization. There is a balance relationship between the power consumption optimization and the damping force optimization of the damper. Therefore, when finding the optimal solution, we should consider the needs of the actual situation and select the most reasonable parameters.

The constantly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) fuel the worldwide coronavirus disease (COVID-19) pandemic. The spike protein is essential for the SARS-CoV-2 viral entry and thus has been extensively targeted by therapeutic antibodies. However, mutations along the spike in SARS-CoV-2 VOC and Omicron subvariants have caused more rapid spread and strong antigenic drifts, rendering most of the current antibodies ineffective. Hence, understanding and targeting the molecular mechanism of spike activation is of great interest in curbing the spread and development of new therapeutic approaches. In this review, we summarize the conserved features of spike-mediated viral entry in various SARS-CoV-2 VOC and highlight the converging proteolytic processes involved in priming and activating the spike. We also summarize the roles of innate immune factors in preventing spike-driven membrane fusion and provide outlines for the identification of novel therapeutics against coronavirus infections.

No abstract

No abstract